- Home
- Companies
- usa rhode island
- tumor targeting
Show results for
Refine by
Tumor Targeting Suppliers Serving Usa Rhode Island
30 companies found
based inSouth San Francisco, CALIFORNIA (USA)
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...
Sutro’s cell-free expression technology provides a rapid and powerful platform for the discovery and development of next generation antibody-drug conjugates ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase ...
based inWest Chester, PENNSYLVANIA (USA)
MTTI is a Clinical Stage Company; Transforming the lives of patients burdened with severe and life-threatening diseases. Advancing selective radiotherapeutics, EBTATE targeting neuroendocrine tumors, EBRGD for non-small cell lung cancer and ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
Immunosynthen is our novel immunostimulatory ADC platform designed to take ADCs beyond traditional cytotoxic drugs to targeted stimulation of the innate immune system. Through the safe and efficient delivery of a novel ...
based inNeedham, MASSACHUSETTS (USA)
Invicro is an integral part of the REALM IDx, Inc. group, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. As a global research partner to the ...
Radiopharmaceutical therapies represent an effective way to treat solid cancers by using tumor targeting small molecules, peptides or biologics to deliver a cytotoxic payload that induces DNA damage in ...
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
4-1BB mAb-based, tumor antigen targeting bispecific ...
based inSão Paulo, BRAZIL
Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
based inSouth San Francisco, CALIFORNIA (USA)
We are dedicated to realizing the potential of natural killer (NK) cells for the treatment of cancer. Our proprietary technology is designed to harness the power of these important pathogen-fighting immune cells and is uniquely capable of enhancing ...
Cell therapy, a new approach that uses immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. First generation approaches have focused on T-cells, which have shown great promise in hematologic ...
based inBerkeley, CALIFORNIA (USA)
SonALAsense’s ALA sonodynamic therapy (SDT) is well differentiated from the use of other forms of therapy which have been used for GBM or rGBM. Our use of a MRI-guided focused ultrasound device with ALA is a true drug-device combination, where both ...
We are committed to providing hope in the face of despair with a unique proprietary non-invasive drug-device combination therapy, ALA Sonodynamic Therapy (SDT), for the treatment of recurrent glioblastoma multiforme (rGBM). ...
based inBellaire, TEXAS (USA)
C4 Imaging develops innovative medical devices that enable clinicians to personalize patient care through accurate image-guided procedures. The company’s core proprietary technology, C4, is a unique magnetic resonance imaging (MRI) agent that has ...
High dose rate (HDR) brachytherapy, utilizing iridium-192 radioactive sources, is a form of radiotherapy and a standard option for the curative treatment of many forms of cancer. 10 HDR brachytherapy involves temporarily placing an applicator into ...
based inShanghai, CHINA
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...
ES101 is a first-in-class tetravalent bispecific antibody targeting 4-1BB and PD-L1. It has a unique mechanism of action as 4-1BB activation is dependent on PD-L1 binding. 4-1BB is a T cell co-stimulatory receptor and is a compelling immune ...
based inSaint-Herblain Cedex, FRANCE
Atlanthera is a drug discovery company focused on bone diseases and bone cancer treatments. The growing medical need and the lack of effective treatments for bone tumors gave rise to Atlanthera in 2011, a drug discovery company focused on bone ...
Specific targeting of tumor bone tissue, Potent antitumor activity, Low systemic toxicity, Prevention of bone ...
based inNanjing, CHINA
ChiRial Biomaterial Co., Ltd. (ChiRial), is a manufacturer of chiral materials through biosynthesis. With 10 years' experience in the field of synthetic biology, the founders of ChiRial have accumulated extensive experience in research, product ...
CRA0066 (R)-5-Methylpyrrolidin-2-one CAS: 21395-93-7. ...
based inWoodinville, WASHINGTON (USA)
Cancer Targeted Technology is designing and patenting small molecular weight enzyme inhibitors with unique and exceptional imaging and drug delivery properties. Cancer Targeted Technology (CTT) develops innovative targeted agents for cancer that ...
based inGarching / Munich, GERMANY
ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes ...
Targeted Radionuclide Therapy (TRT) or Peptide Receptor Radionuclide Therapy (PRRT) is a medical specialty using very small amounts of radioactive compounds, called radiopharmaceuticals, to diagnose and treat various diseases, like ...
based inSan Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
T cells engineered with chimeric antigen receptors (CARs) have shown exceptional promise as a potentially curative therapy for patients with certain hematologic malignancies. While most researchers and clinical investigators continue to focus on the ...
based inMonroe Township, NEW JERSEY (USA)
We are a multinational company active in the life science sector, a world leader in imaging diagnostics. Every day we seek and perfect increasingly advanced and sustainable techniques and solutions to open new paths in diagnostic imaging. So that ...
Nuclear medicine is a specialized field of medicine using radioactive tracers (radiopharmaceuticals) that are either injected into or ingested by the patient. Specially designed cameras allow doctors to track the distribution, uptake, and ...
based inBasel, SWITZERLAND
Nuclidium AG specializes in leveraging the unique properties of copper radionuclides in conjunction with tumor-specific molecules to enhance the precision, performance, and accessibility of targeted radiotherapy and diagnostics. Their proprietary ...
Nuclidium AG leverages the unique properties of copper radionuclides to advance precision radiotherapy and diagnostics. Their proprietary CuTrace™ platform combines copper nuclides with tumor-specific molecules, creating ...
based inPrinceton, NEW JERSEY (USA)
The drug discovery and development process is long and expensive with more failures than successes. At Certara, we anticipate and address your critical drug discovery and development risks and decisions using biosimulation, technology and services. ...
Biological medicines (“biologics” or “large molecule drugs”) now account for 30% of new drug approvals and up to 50% of the pharmaceutical industry’s pipeline. Biologics differ from small molecules because they are much ...